You are here

  • Home
  • Archive
  • Volume 4, Issue 2
  • Direct delivery of an investigational cell therapy in patients with Parkinson’s disease: an interim analysis of feasibility and safety of an open-label study using DBS-Plus clinical trial design

Citation Tools

Article menu
Original research
Direct delivery of an investigational cell therapy in patients with Parkinson’s disease: an interim analysis of feasibility and safety of an open-label study using DBS-Plus clinical trial design

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Quintero JE, Slevin JT, Gurwell JA, et al
Direct delivery of an investigational cell therapy in patients with Parkinson’s disease: an interim analysis of feasibility and safety of an open-label study using DBS-Plus clinical trial design
BMJ Neurology Open 2022;4:e000301. doi: 10.1136/bmjno-2022-000301